On January 14, RH director Mark Demilio executed a sale of 2,254 shares of company stock, representing a 10.15% reduction in his holdings. Following the transaction, he retains 19,962 shares. The sale, disclosed in an SEC filing, underscores a notable shift in insider conviction and will be closely watched by investors sensitive to executive-level trading activity.

RH reported fourth-quarter revenue of $883.8 million, reflecting year-over-year growth of 8.9% and matching consensus estimates. However, EPS of 1.71 fell short of analyst forecasts by 0.42, driving the net margin down to 3.22% and resulting in a negative return on equity of 161.7%. While top-line expansion remained intact, margin pressures and elevated leverage continue to weigh on profitability metrics.

Analyst opinion on RH is polarized: Morgan Stanley raised its target materially, citing sustained revenue growth and potential for a multiple re-rating, while other firms have trimmed targets or maintained hold ratings based on mixed margin trajectories and wide estimate dispersion. Institutional activity has likewise been uneven, with large funds both adding to and reducing stakes, leaving the stock’s near-term direction dependent on future earnings execution and balance sheet improvements.